Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.47 |
| ▸ | DAO | P14920 | 1/20 | 0.44 |
| ▸ | KMO | O15229 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 5/20 | 0.44 |
| ▸ | ALPI | P09923 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | XIAP | P98170 | 1/20 | 0.42 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.42 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29410439 | 1.00 | SIRT1 (0.47) | SIRT1DAOKMOCYP1A2CYP3A4 | |
| SCHEMBL456666 | 1.00 | SIRT1 (0.47) | SIRT1DAOKMOCYP1A2CYP3A4 | |
| SCHEMBL11033505 | 0.89 | SIRT1 (0.61) | SIRT1DAOCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL29410437 | 0.83 | SLC7A5 (0.42) | CYP3A4ALOX15ALPIPKMPTGS1 | |
| SCHEMBL456003 | 0.83 | SLC7A5 (0.42) | CYP3A4ALOX15ALPIPKMPTGS1 | |
| SCHEMBL456004 | 0.83 | SLC7A5 (0.42) | CYP3A4ALOX15ALPIPKMPTGS1 | |
| SCHEMBL29440959 | 0.81 | ALPI (0.54) | DAOALPIPKMPTGS1XIAP | |
| SCHEMBL29574121 | 0.81 | ALPI (0.54) | DAOALPIPKMPTGS1XIAP | |
| SCHEMBL4393088 | 0.81 | ALPI (0.54) | DAOALPIPKMPTGS1XIAP | |
| SCHEMBL45382 | 0.81 | ALPI (0.54) | DAOALPIPKMPTGS1XIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 181 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9771263-B2 | Crystals of semiconductor material having a tuned band gap energy and method for preparation thereof | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2017-09-26 | — | — | US | claimed |
| US-20150090942-A1 | CRYSTALS OF SEMICONDUCTOR MATERIAL HAVING A TUNED BAND GAP ENERGY AND METHOD FOR PREPARATION THEREOF | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2015-04-02 | — | — | US | claimed |
| US-8980581-B2 | Site-specific incorporation of amino acids into molecules | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2015-03-17 | — | — | US | claimed |
| US-20140045261-A1 | SITE-SPECIFIC INCORPORATION OF AMINO ACIDS INTO MOLECULES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2014-02-13 | — | — | US | claimed |
| US-8518666-B2 | Site-specific incorporation of amino acids into molecules | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2013-08-27 | — | — | US | claimed |
| EP-2444499-A2 | Amino acid substituted molecules | Allozyne, Inc. (US) | 2012-04-25 | — | — | EP | claimed |
| US-20100254943-A1 | AMINO ACID SUBSTITUTED MOLECULES | ALLOZYNE, INC. (US) | 2010-10-07 | — | — | US | claimed |
| EP-2190856-A2 | POLYPEPTIDES WITH MODIFIED AMINO ACIDS | Allozyne, Inc. (US) | 2010-06-02 | — | — | EP | claimed |
| WO-2009026393-A2 | AMINO ACID SUBSTITUTED MOLECULES | ALLOZYNE, INC. (US) | 2009-02-26 | — | — | WO | claimed |
| EP-2018437-A2 | NON-NATURAL AMINO ACID SUBSTITUTED POLYPEPTIDES | Allozyne, Inc. (US) | 2009-01-28 | — | — | EP | claimed |
| EP-1999259-A2 | SITE-SPECIFIC INCORPORATION OF AMINO ACIDS INTO MOLECULES | California Institute of Technology (US) | 2008-12-10 | — | — | EP | claimed |
| US-20080214439-A1 | AMINO ACID SUBSTITUTED MOLECULES | ALLOZYNE, INC. (US) | 2008-09-04 | — | — | US | claimed |
| US-20080125347-A1 | AMINO ACID SUBSTITUTED MOLECULES | ALLOZYNE, INC. (US) | 2008-05-29 | — | — | US | claimed |
| US-20080096819-A1 | Amino acid substituted molecules | ALLOZYNE, INC. (US) | 2008-04-24 | — | — | US | claimed |
| US-20080044854-A1 | SITE-SPECIFIC INCORPORATION OF AMINO ACIDS INTO MOLECULES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2008-02-21 | — | — | US | claimed |
| WO-2007130453-A2 | NON-NATURAL AMINO ACID SUBSTITUTED POLYPEPTIDES | ALLOZYNE, INC. (US) | 2007-11-15 | — | — | WO | claimed |
| WO-2007103307-A2 | SITE-SPECIFIC INCORPORATION OF AMINO ACIDS INTO MOLECULES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2007-09-13 | — | — | WO | claimed |
| EP-4100044-B1 | COMPOSITIONS COMPRISING AMELOGENIN AND USES THEREOF | PRUDENTIX LTD (IL) | 2026-04-01 | — | — | EP | disclosed |
| WO-2007130453-A2 | NON-NATURAL AMINO ACID SUBSTITUTED POLYPEPTIDES | ALLOZYNE, INC. (US) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007103307-A2 | SITE-SPECIFIC INCORPORATION OF AMINO ACIDS INTO MOLECULES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2007-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096819-A1 | Amino acid substituted molecules | BCAT2, DNPEP, PTMS | SIRT1 3759/4885DAO 12/4885KMO 484/4885 |
| US-20080214439-A1 | AMINO ACID SUBSTITUTED MOLECULES | BCAT2, DNPEP, PTMS | SIRT1 3759/4885DAO 12/4885KMO 484/4885 |
| US-20100254943-A1 | AMINO ACID SUBSTITUTED MOLECULES | BCAT2, DNPEP, PTMS | SIRT1 3759/4885DAO 12/4885KMO 484/4885 |
| US-20080044854-A1 | SITE-SPECIFIC INCORPORATION OF AMINO ACIDS INTO MOLECULES | AARS1, TRMT1, NSUN3 | SIRT1 4555/4885DAO 42/4885KMO 1383/4885 |
| US-20080125347-A1 | AMINO ACID SUBSTITUTED MOLECULES | BCAT2, DNPEP, PTMS | SIRT1 3759/4885DAO 12/4885KMO 484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.